Barclays
HZNP

Barclays’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Barclays’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-248,600
Closed -$28.3M – 5587
2022
Q4 		$28.3M Buy
+248,600
New +$20.6M 0.01% 720
2020
Q4 		– Sell
-1,200
Closed -$93K – 5321
2020
Q3 		$93K Hold
1,200
– – ﹤0.01% 4296
2020
Q2 		$67K Sell
1,200
-1,100
-48% -$47.1K ﹤0.01% 4780
2020
Q1 		$68K Sell
2,300
-10,200
-82% -$345K ﹤0.01% 5034
2019
Q4 		$453K Sell
12,500
-800
-6% -$24.5K ﹤0.01% 4385
2019
Q3 		$362K Sell
13,300
-4,800
-27% -$124K ﹤0.01% 4512
2019
Q2 		$435K Sell
18,100
-78,400
-81% -$1.99M ﹤0.01% 4447
2019
Q1 		$2.55M Buy
96,500
+60,400
+167% +$1.43M ﹤0.01% 2316
2018
Q4 		$705K Sell
36,100
-4,800
-12% -$94.1K ﹤0.01% 3475
2018
Q3 		$801K Sell
40,900
-11,300
-22% -$215K ﹤0.01% 3852
2018
Q2 		$864K Buy
52,200
+2,900
+6% +$44.2K ﹤0.01% 3446
2018
Q1 		$700K Buy
49,300
+8,700
+21% +$129K ﹤0.01% 3613
2017
Q4 		$593K Buy
40,600
+28,200
+227% +$396K ﹤0.01% 3627
2017
Q3 		$157K Sell
12,400
-1,100
-8% -$14K ﹤0.01% 4616
2017
Q2 		$160K Sell
13,500
-1,222,300
-99% -$15.2M ﹤0.01% 4555
2017
Q1 		$18.3M Sell
1,235,800
-1,857,900
-60% -$30.1M 0.02% 593
2016
Q4 		$50.1M Buy
+3,093,700
New +$56.1M 0.05% 276
2016
Q3 		– Sell
-24,900
Closed -$410K – 6921
2016
Q2 		$410K Buy
+24,900
New +$403K ﹤0.01% 3372
2015
Q4 		– Sell
-213,200
Closed -$4.05M – 6908
2015
Q3 		$4.05M Buy
+213,200
New +$6.74M ﹤0.01% 1514
2015
Q1 		– Sell
-471,800
Closed -$5.66M – 7348
2014
Q4 		$5.66M Hold
471,800
– – 0.01% 1592
2014
Q3 		$5.66M Hold
471,800
– – 0.01% 1657
2014
Q2 		$7.08M Hold
471,800
– – 0.01% 1434
2014
Q1 		$7.08M Buy
+471,800
New +$5.33M 0.01% 1431

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's HZNP Position: Q4 2023 in Review

Barclays sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 699,553 shares — an estimated $80.9M sold.

Barclays first reported a position in HZNP in Q2 2013 and held it in 42 quarters. The position peaked at $238M in Q3 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Barclays reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Barclays sold 699,553 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $80.9M.
  • Barclays first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 42 quarters.
  • Barclays's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $238M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.